Panel Discussion
*Telba Irony, FDA  *Qi Jiang, Amgen  *John Scott, CBER FDA   *Ellis Unger , FDA CDER 

Keywords: QSPI, Benefit-risk

The panel will discuss the work to date by the QSPI Benefit-Risk Working Group and provide guidance and thought on future work.